ABSTRACT
Mucormycosis is an emerging and slowly rising fatal infectious disease in most countries. It is the third most common invasive mycosis after candidiasis and aspergillosis. Hematologic malignancies notably acute myeloblastic leukemia (AML) and diabetes mellitus (DM) especially when uncontrolled or there is ketoacidosis are the most common predisposing conditions. Clinical manifestations vary according to the organ involved. Based on anatomic localization, mucormycosis can be classified as one of 6 forms: Rhinocerebral, Pulmonary, Cutaneous, Gastrointestinal, Disseminated and Uncommon presentations. The mortality rate is often very high. Early diagnosis and aggressive treatment are the cornerstone of management. Here we report 5 cases of mucormycosis in patients admitted to Imam Reza hospital, the tertiary referral center in Northwest of Iran. We will also have a brief review of this fungal infection.
ABSTRACT
To compare efficiency of cryotherapy followed by Acnalen gel 0.1% with cryotherapy plus placebo in the treatment of AKs [Actinic Keratosis]. One hundred outpatients who had a clinical diagnosis of actinic keratoses on face or scalp with at least five lesions were enrolled in the study. Patients were randomized into two groups: cryotherapy plus placebo and cryotherapy plus Acnalen 0.1% gel for a period of 100 days. Lesion counts were assessed at baseline, and 40, 70 and 100 days after cryotherapy. Mean baseline number of lesions for cryotherapy plus Acnalen gel group and cryotherapy plus placebo group were 7.54 +/- 3.66 and 7.20 +/- 3.60. In Acnalen group mean number of lesions reduced to 3.44 +/- 2.71[54.79 +/- 3.8%] and in placebo group reduced to 3.68 +/- 2.97 [48.60 +/- 4.5%] [P=0.62]. Our results suggested that cryotherapy and Acnalen 0.1% gel during 100 days cannot be more helpful than cryotherapy alone in the treatment of clinical AKs